Intelligence · Patents
Patents expiring in 2040
Annual patent cliff calendar for 2040 — US pharmaceutical patents by expiration date.
- Patents
- 1,866
Quick answer
1,866 indexed pharmaceutical patents have expiration dates in 2040. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10646591
Imaging agents for imaging protease activity and uses thereof
granted -
US 10646578
Polymer derivatives having particular atom arrangements
granted -
US 10647785
High concentration chitosan-nucleic acid polyplex compositions
granted -
US 10646593
Activatable membrane-interacting peptides and methods of use
granted -
US 10646588
RP2 and RPGR vectors for treating X-linked retinitis pigmentosa
granted -
US 10646575
Heterocyclic degronimers for target protein degradation
granted -
US 10646574
Formulations of intraarticular pharmaceutical agents and methods for preparing and using the same
granted -
US 10646557
Vaccine composition
granted -
US 10646555
Compositions and methods relating to argininosuccinate synthetase
granted -
US 10646543
Methods and compositions for treating trinucleotide repeat disorders
granted -
US 10646523
Combination comprising spirulina and palmitoylethanolamide and/or salts or pharmaceutically acceptable derivatives thereof and their formulations, for use in the prevention and/or in the treatment of hyperactivated tissue conditions
granted -
US 10646517
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
granted -
US 10646484
Methods to treat opioid use disorder
granted -
US 10646485
Process of making stable abuse-deterrent oral formulations
granted -
US 10646474
Glucocorticoid receptor modulators to treat pancreatic cancer
granted -
US 10646480
Formulations of pimavanserin
granted -
US 10646443
Sustained release olanzapine formulations
granted -
US 10646435
Pasty bio-adhesive sustained release compositions
granted -
US 10647710
Thiazole derivative and applications thereof
granted -
US 10646537
Traditional Chinese medicine for treating abdominal obesity
granted -
US 10646438
Methods for inducing an immune response via buccal and/or sublingual administration of a vaccine
granted -
US 10646475
SHMT inhibitors
granted -
US 10646577
mTORC1 inhibitors
granted -
US 10647711
Azepin-2-one derivatives as RSV inhibitors
granted -
WO 2020095183
COMBINAISON POUR LE TRAITEMENT DU CANCER
granted -
WO 2020094634
PROMÉDICAMENTS DE THIOPHÈNE DE NALTROXÈNE POUR COMPOSITIONS INJECTABLES À ACTION PROLONGÉE ET PROCÉDÉS ASSOCIÉS
granted -
US 10654898
Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/BPIV3 F protein and uses thereof
granted -
US 10655109
Recombinant respiratory syncytial virus stains with mutations in the M2-2 ORF providing a range of attenuation phenotypes
granted -
US 10654864
Modified cytotoxins and their therapeutic use
granted -
US 10655183
Carcinoma diagnosis and treatment based on ODC1 genotype
granted -
US 10653723
Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
granted -
US 10653789
Polymer-drug conjugates for combination anticancer therapy
granted -
US 10654802
Indoline derivatives and method for using and producing the same
granted -
US 10653665
Method of treatment
granted -
US 10653150
Shelf life and color profile of resin compositions with silver nanoparticles
granted -
US 10653689
Combination-based treatment method
granted -
US 10655129
Compositions and their uses directed to huntingtin
granted -
US 10653169
Food thickening agent, method for producing food thickening agent
granted -
US 10653710
Combination therapy for treating malignancies
granted -
US 10654916
Compositions and methods for the treatment of neuromyelitis optica
granted -
US 10654874
Heterocyclic compound and use thereof
granted -
US 10655103
Equine progenitor cells
granted -
US 10654829
Crystalline forms and compositions of CFTR modulators
granted -
US 10654834
Non-systemic TGR5 agonists
granted -
US 10653803
Cellular micromotors and uses thereof
granted -
US 10654842
Dopamine D3 receptor antagonist compounds
granted -
US 10653774
Compositions and methods for activating “stimulator of interferon gene”-dependent signalling
granted -
US 10653797
Compounds and compositions for targeting brain injuries and methods of use thereof
granted
Frequently asked questions
How many pharma patents expire in 2040?
1,866 published patents in our USPTO index have expiration dates falling in calendar year 2040.